Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis
Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil ® ) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was meas...
Gespeichert in:
| Veröffentlicht in: | European archives of oto-rhino-laryngology 2016-10, Vol.273 (10), p.3231-3236 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3236 |
|---|---|
| container_issue | 10 |
| container_start_page | 3231 |
| container_title | European archives of oto-rhino-laryngology |
| container_volume | 273 |
| creator | Tjon Pian Gi, Robin E. A. San Giorgi, Michel R. M. Pawlita, Michael Michel, Angelika van Hemel, Bettien M. Schuuring, Ed M. D. van den Heuvel, Edwin R. van der Laan, Bernard F. A. M. Dikkers, Frederik G. |
| description | Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil
®
) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (
p
|
| doi_str_mv | 10.1007/s00405-016-4085-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5014878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1818337093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-2035c7a7ec3b7adaad9047e00026d8343d80aeea648dac871c58ba6e42ca52823</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCIbgs_gAvKkUtg_JHYe0FCFdBKleAAXK1ZZ3Zx5dipnazUf4-jLVW5cBqN3sc8zWPsDYf3HEB_KAAKuhZ43yowXSufsQ1XUrVKi_4528BW6lYprc_YeSm3ANCprXzJzoTmxnRgNuxwPY5LTCEdvMPQZCpTioWaOTV3Cw7ZHzFQnJur77-aIzrnIzU-NnMmnMcVSPsqckvO67LKfcY55ftmwsmHkMa6FV9esRd7DIVeP8wL9vPL5x-XV-3Nt6_Xl59uWqeUmFsBsnMaNTm50zggDltQmmpy0Q9GKjkYQCLslRnQGc1dZ3bYkxIOO2GEvGAfT77TshtpcDVVxmCn7EfM9zaht_8i0f-2h3S0HXBltKkG7x4McrpbqMx29MVRCBgpLcVyw42Uur62UvmJ6nIqJdP-8QwHuxZkTwXZWpBdC7Kr5u3TfI-Kv41UgjgRSoXigbK9TUuO9Wf_cf0D8_yffQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818337093</pqid></control><display><type>article</type><title>Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Tjon Pian Gi, Robin E. A. ; San Giorgi, Michel R. M. ; Pawlita, Michael ; Michel, Angelika ; van Hemel, Bettien M. ; Schuuring, Ed M. D. ; van den Heuvel, Edwin R. ; van der Laan, Bernard F. A. M. ; Dikkers, Frederik G.</creator><creatorcontrib>Tjon Pian Gi, Robin E. A. ; San Giorgi, Michel R. M. ; Pawlita, Michael ; Michel, Angelika ; van Hemel, Bettien M. ; Schuuring, Ed M. D. ; van den Heuvel, Edwin R. ; van der Laan, Bernard F. A. M. ; Dikkers, Frederik G.</creatorcontrib><description>Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil
®
) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (
p
< 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.</description><identifier>ISSN: 0937-4477</identifier><identifier>EISSN: 1434-4726</identifier><identifier>DOI: 10.1007/s00405-016-4085-3</identifier><identifier>PMID: 27188508</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Antibodies, Viral - blood ; Female ; Head and Neck Surgery ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use ; Humans ; Laryngology ; Male ; Medicine ; Medicine & Public Health ; Neurosurgery ; Otorhinolaryngology ; Papillomaviridae - immunology ; Papillomavirus Infections - prevention & control ; Papillomavirus Infections - surgery ; Regression Analysis ; Respiratory Tract Infections - prevention & control ; Respiratory Tract Infections - surgery ; Retrospective Studies</subject><ispartof>European archives of oto-rhino-laryngology, 2016-10, Vol.273 (10), p.3231-3236</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-2035c7a7ec3b7adaad9047e00026d8343d80aeea648dac871c58ba6e42ca52823</citedby><cites>FETCH-LOGICAL-c442t-2035c7a7ec3b7adaad9047e00026d8343d80aeea648dac871c58ba6e42ca52823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00405-016-4085-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00405-016-4085-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27188508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tjon Pian Gi, Robin E. A.</creatorcontrib><creatorcontrib>San Giorgi, Michel R. M.</creatorcontrib><creatorcontrib>Pawlita, Michael</creatorcontrib><creatorcontrib>Michel, Angelika</creatorcontrib><creatorcontrib>van Hemel, Bettien M.</creatorcontrib><creatorcontrib>Schuuring, Ed M. D.</creatorcontrib><creatorcontrib>van den Heuvel, Edwin R.</creatorcontrib><creatorcontrib>van der Laan, Bernard F. A. M.</creatorcontrib><creatorcontrib>Dikkers, Frederik G.</creatorcontrib><title>Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis</title><title>European archives of oto-rhino-laryngology</title><addtitle>Eur Arch Otorhinolaryngol</addtitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><description>Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil
®
) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (
p
< 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.</description><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Female</subject><subject>Head and Neck Surgery</subject><subject>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use</subject><subject>Humans</subject><subject>Laryngology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurosurgery</subject><subject>Otorhinolaryngology</subject><subject>Papillomaviridae - immunology</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Infections - surgery</subject><subject>Regression Analysis</subject><subject>Respiratory Tract Infections - prevention & control</subject><subject>Respiratory Tract Infections - surgery</subject><subject>Retrospective Studies</subject><issn>0937-4477</issn><issn>1434-4726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQtRCIbgs_gAvKkUtg_JHYe0FCFdBKleAAXK1ZZ3Zx5dipnazUf4-jLVW5cBqN3sc8zWPsDYf3HEB_KAAKuhZ43yowXSufsQ1XUrVKi_4528BW6lYprc_YeSm3ANCprXzJzoTmxnRgNuxwPY5LTCEdvMPQZCpTioWaOTV3Cw7ZHzFQnJur77-aIzrnIzU-NnMmnMcVSPsqckvO67LKfcY55ftmwsmHkMa6FV9esRd7DIVeP8wL9vPL5x-XV-3Nt6_Xl59uWqeUmFsBsnMaNTm50zggDltQmmpy0Q9GKjkYQCLslRnQGc1dZ3bYkxIOO2GEvGAfT77TshtpcDVVxmCn7EfM9zaht_8i0f-2h3S0HXBltKkG7x4McrpbqMx29MVRCBgpLcVyw42Uur62UvmJ6nIqJdP-8QwHuxZkTwXZWpBdC7Kr5u3TfI-Kv41UgjgRSoXigbK9TUuO9Wf_cf0D8_yffQ</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Tjon Pian Gi, Robin E. A.</creator><creator>San Giorgi, Michel R. M.</creator><creator>Pawlita, Michael</creator><creator>Michel, Angelika</creator><creator>van Hemel, Bettien M.</creator><creator>Schuuring, Ed M. D.</creator><creator>van den Heuvel, Edwin R.</creator><creator>van der Laan, Bernard F. A. M.</creator><creator>Dikkers, Frederik G.</creator><general>Springer Berlin Heidelberg</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161001</creationdate><title>Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis</title><author>Tjon Pian Gi, Robin E. A. ; San Giorgi, Michel R. M. ; Pawlita, Michael ; Michel, Angelika ; van Hemel, Bettien M. ; Schuuring, Ed M. D. ; van den Heuvel, Edwin R. ; van der Laan, Bernard F. A. M. ; Dikkers, Frederik G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-2035c7a7ec3b7adaad9047e00026d8343d80aeea648dac871c58ba6e42ca52823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Female</topic><topic>Head and Neck Surgery</topic><topic>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use</topic><topic>Humans</topic><topic>Laryngology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurosurgery</topic><topic>Otorhinolaryngology</topic><topic>Papillomaviridae - immunology</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Infections - surgery</topic><topic>Regression Analysis</topic><topic>Respiratory Tract Infections - prevention & control</topic><topic>Respiratory Tract Infections - surgery</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tjon Pian Gi, Robin E. A.</creatorcontrib><creatorcontrib>San Giorgi, Michel R. M.</creatorcontrib><creatorcontrib>Pawlita, Michael</creatorcontrib><creatorcontrib>Michel, Angelika</creatorcontrib><creatorcontrib>van Hemel, Bettien M.</creatorcontrib><creatorcontrib>Schuuring, Ed M. D.</creatorcontrib><creatorcontrib>van den Heuvel, Edwin R.</creatorcontrib><creatorcontrib>van der Laan, Bernard F. A. M.</creatorcontrib><creatorcontrib>Dikkers, Frederik G.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European archives of oto-rhino-laryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tjon Pian Gi, Robin E. A.</au><au>San Giorgi, Michel R. M.</au><au>Pawlita, Michael</au><au>Michel, Angelika</au><au>van Hemel, Bettien M.</au><au>Schuuring, Ed M. D.</au><au>van den Heuvel, Edwin R.</au><au>van der Laan, Bernard F. A. M.</au><au>Dikkers, Frederik G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis</atitle><jtitle>European archives of oto-rhino-laryngology</jtitle><stitle>Eur Arch Otorhinolaryngol</stitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>273</volume><issue>10</issue><spage>3231</spage><epage>3236</epage><pages>3231-3236</pages><issn>0937-4477</issn><eissn>1434-4726</eissn><abstract>Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil
®
) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (
p
< 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27188508</pmid><doi>10.1007/s00405-016-4085-3</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-4477 |
| ispartof | European archives of oto-rhino-laryngology, 2016-10, Vol.273 (10), p.3231-3236 |
| issn | 0937-4477 1434-4726 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5014878 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Antibodies, Viral - blood Female Head and Neck Surgery Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use Humans Laryngology Male Medicine Medicine & Public Health Neurosurgery Otorhinolaryngology Papillomaviridae - immunology Papillomavirus Infections - prevention & control Papillomavirus Infections - surgery Regression Analysis Respiratory Tract Infections - prevention & control Respiratory Tract Infections - surgery Retrospective Studies |
| title | Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T21%3A20%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunological%20response%20to%20quadrivalent%20HPV%20vaccine%20in%20treatment%20of%20recurrent%20respiratory%20papillomatosis&rft.jtitle=European%20archives%20of%20oto-rhino-laryngology&rft.au=Tjon%20Pian%20Gi,%20Robin%20E.%20A.&rft.date=2016-10-01&rft.volume=273&rft.issue=10&rft.spage=3231&rft.epage=3236&rft.pages=3231-3236&rft.issn=0937-4477&rft.eissn=1434-4726&rft_id=info:doi/10.1007/s00405-016-4085-3&rft_dat=%3Cproquest_pubme%3E1818337093%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1818337093&rft_id=info:pmid/27188508&rfr_iscdi=true |